Physician profile
Crystal Abraham
NPI 1447964259
$4,678.95
in general payments reported to CMS, 2019-2025
24 companies · $1,923 in 2025
The $1,923 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $17.17 · 2023: $986 · 2024: $1,753 · 2025: $1,923.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,563 · Education: $98.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,563.06 |
| Education | $98.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $889.23 | 2023-2025 | Rinvoq, Skyrizi |
| Janssen Biotech, INC. | $856.20 | 2023-2025 | Tremfya, Stelara |
| Ardelyx, INC. | $510.76 | 2023-2025 | Ibsrela |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $457.43 | 2023-2025 | Trulance, Xifaxan, Relistor |
| Takeda Pharmaceuticals U.S.A., INC. | $444.16 | 2023-2025 | Entyvio, Gattex, Eohilia |
| Qol Medical, LLC | $313.11 | 2023-2025 | Sucraid, Sucraid |
| Phathom Pharmaceuticals, INC. | $214.37 | 2024-2025 | Voquezna |
| Celgene Corporation | $184.76 | 2023-2024 | Zeposia |
| Pfizer INC. | $147.42 | 2023-2025 | |
| Genzyme Corporation | $91.95 | 2023-2025 | |
| Lilly USA, LLC | $90.41 | 2023-2025 | Omvoh |
| Ipsen Biopharmaceuticals, INC | $87.73 | 2024-2025 | Iqirvo |
| Gilead Sciences, INC. | $69.48 | 2025 | |
| Intercept Pharmaceuticals, INC. | $59.32 | 2025 | |
| Aimmune Therapeutics, INC. | $56.97 | 2024-2025 | Zenpep |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $33.83 | 2025 | The Cologuard Plus Collection Kit |
| Ironwood Pharmaceuticals, INC | $32.79 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $30.34 | 2023 | Dupixent |
| Nestle Healthcare Nutrition INC. | $28.93 | 2023 | |
| Janssen Pharmaceuticals, INC | $19.72 | 2025 | |
| Metacel Pharmaceuticals LLC | $17.17 | 2022 | |
| Shield Therapeutics INC | $16.24 | 2024 | |
| Novo Nordisk INC | $13.52 | 2025 | Wegovy |
| Madrigal Pharmaceuticals | $13.11 | 2024 | Resmetirom |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Crystal Abraham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.